JASPER THERAPEUTICS, INC. Other Operating Activities, Cash Flow Statement
JASPER THERAPEUTICS, INC. (JSPR) reported Other Operating Activities, Cash Flow Statement of $23.60 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherOperatingActivitiesCashFlowStatement · last filed 2023-08-11
- JASPER THERAPEUTICS, INC. other operating activities, cash flow statement for the quarter ending 2022-12-31 was $12.70M, a 13.01% decline year-over-year.
- JASPER THERAPEUTICS, INC. other operating activities, cash flow statement for the quarter ending 2022-09-30 was $9.60M.
- JASPER THERAPEUTICS, INC. other operating activities, cash flow statement for the quarter ending 2022-06-30 was $9.40M, a 21.67% decline year-over-year.
- JASPER THERAPEUTICS, INC. other operating activities, cash flow statement for the quarter ending 2022-03-31 was $14.20M, a 129.03% increase year-over-year.
- JASPER THERAPEUTICS, INC. other operating activities, cash flow statement for fiscal 2022 was $45.90M, a 36.20% increase from fiscal 2021.
- JASPER THERAPEUTICS, INC. other operating activities, cash flow statement for fiscal 2021 was $33.70M, a 84.15% increase from fiscal 2020.
- JASPER THERAPEUTICS, INC. other operating activities, cash flow statement for fiscal 2020 was $18.30M.
| Period end | Other Operating Activities, Cash Flow Statement 3 month | Other Operating Activities, Cash Flow Statement 6 month | Other Operating Activities, Cash Flow Statement 9 month | Other Operating Activities, Cash Flow Statement 12 month |
|---|---|---|---|---|
| 2023-06-30 | $23.60M 10-Q · filed 2023-08-11 | |||
| 2022-12-31 | $12.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $22.30M derived: sum of 2 quarters · filed 2023-03-08 | $31.70M derived: sum of 3 quarters · filed 2023-03-08 | $45.90M 10-K · filed 2023-03-08 |
| 2022-09-30 | $9.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $19.00M derived: sum of 2 quarters · filed 2022-11-10 | $33.20M 10-Q · filed 2022-11-10 | $47.80M derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-06-30 | $9.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $23.60M 10-Q · filed 2022-08-12 | $38.20M derived: sum of 3 quarters · filed 2023-05-12 | |
| 2022-03-31 | $14.20M 10-Q · filed 2023-05-12 | $28.80M derived: sum of 2 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $14.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $33.70M 10-K · filed 2023-03-08 | ||
| 2021-09-30 | $19.10M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $12.00M 10-Q · filed 2022-08-12 | $18.20M derived: sum of 2 quarters · filed 2022-08-12 | $23.60M derived: sum of 3 quarters · filed 2022-08-12 | |
| 2021-03-31 | $6.20M 10-Q · filed 2022-05-12 | $11.60M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $18.30M 10-K · filed 2022-03-18 | ||
| 2020-09-30 | $12.90M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |